Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity

Novo Holdings, the holding company of Novo Nordisk, will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss drug Wegovy, the companies said on Monday. Under the deal, Novo Holdings will buy all outstanding…#novoholdings #novonordisk #catalent #novo #danish
Source: Reuters: Health - Category: Consumer Health News Source Type: news